I am a
Home I AM A Search Login

Papers of the Week

2020 Apr

CNS Spectr



170 Efficacy and Safety of Dasotraline in Adults with Binge-Eating Disorder: A Randomized, Double-blind, Fixed-dose Trial.


Tsai J, Navia B, McElroy SL, Hudson JI, Grilo CM, Goldman R, Deng L, Kent J, Loebel A
CNS Spectr. 2020 Apr; 25(2):308-309.
PMID: 32331033.


Dasotraline is a long-acting dopamine/norepinephrine reuptake inhibitor with a PK profile characterized by slow absorption and a t½ of 47-77 hours, permitting once-daily dosing. In a previous flexible dose study, dasotraline demonstrated significant efficacy in the treatment of binge-eating disorder (BED). The aim of this confirmatory fixed-dose study was to evaluate efficacy and safety of dasotraline in the treatment of patients with BED.